Evidence map›Paper›PMID 36419881›Full record

ArticleFrontiers in oncology2022

Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy.

Margaret M Kozak, David Crompton, Brandie A Gross, Lyndsay Harshman, David Dickens, Jeffrey Snyder, Andrew Shepard, Joël St-Aubin, David Dunkerley, Daniel Hyer and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Margaret M KozakDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
David CromptonDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Brandie A GrossDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Lyndsay HarshmanDepartment of Pediatrics, the University of Iowa Hospitals and Clinics, Iowa, IA, United States.
David DickensDepartment of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Jeffrey SnyderDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Andrew ShepardDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Joël St-AubinDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
David DunkerleyDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
Daniel HyerDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
John M BuattiDepartment of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa, IA, United States.
University of Iowa Hospitals and Clinics · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
University of Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (Hawk-IDDRC)P50HD103556 · NICHD · UNIVERSITY OF IOWA · PI Lane Strathearn · 2021 to 2026
$8.5M
NICHD NIH HHS P50 HD103556
6 · The paper itself

Abstract

Purpose: To demonstrate the clinical applications and feasibility of online adaptive magnetic resonance image guided radiotherapy (MRgRT) in the pediatric, adolescent and young adult (AYA) population. Methods: This is a retrospective case series of patients enrolled onto a prospective study. All pediatric (age < 18) and AYA patients (age< 30), treated on the Elekta Unity MR linear accelerator (MRL) from 2019 to 2021 were enrolled onto a prospective registry. Rationale for MRgRT included improved visualization of and alignment to the primary tumor, re-irradiation in a critical area, ability to use smaller margins, and need for daily adaptive replanning to minimize dose to adjacent critical structures. Step-and-shoot intensity-modulated radiation treatment (IMRT) plans were generated for all Unity patients with a dose grid of 3 mm and a statistical uncertainty of < 1% per plan. Results: A total of 15 pediatric and AYA patients have been treated with median age of 13 years (range: 6 mos - 27 yrs). Seven patients were <10 yo. The clinical applications of MRgRT included Wilms tumor with unresectable IVC thrombus (n=1), Ewing sarcoma (primary and metastatic, n=3), recurrent diffuse intrinsic pontine glioma (DIPG, n=2), nasopharyngeal carcinoma (n=1), clival chordoma (n=1), primitive neuroectodermal tumor of the pancreas (n=1), recurrent gluteo-sacral germ cell tumor (n=1), C-spine ependymoma (n=1), and posterior fossa ependymoma (n=1). Two children required general anesthesia. One AYA patient could not complete the MRgRT course due to tumor-related pain exacerbated by longer treatment times. Two AYA patients experienced anxiety related to treatment on the MRL, one of which required daily Ativan. No patient experienced treatment interruptions or unexpected toxicity. Conclusion: MRgRT was well-tolerated by pediatric and AYA patients. There was no increased use of anesthesia outside of our usual practice. Dosimetric advantages were seen for patients with tumors in critical locations such as adjacent to or involving optic structures, stomach, kidney, bowel, and heart.

Indexed as

adolescentcancerMR guidancepediatricradiotherapy

Identifiers

PMID36419881
PMCPMC9676495
OpenAlexW4308440766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.